Arcus Biosciences Inc. has amended its existing Loan and Security Agreement with Hercules Capital, Inc. and a group of lenders, enhancing its access to up to $150 million in additional term loan commitments. Under the terms of the First Amendment, Arcus may draw $25 million at its discretion through March 15, 2026, another $25 million through September 15, 2026, up to $50 million upon achieving key clinical milestones, and an additional $50 million following FDA approval of a Biologics License Application or New Drug Application. The amendment also extends the loan maturity date to September 1, 2030, and introduces new financial performance covenants if the outstanding principal exceeds $200 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001724521-25-000122), on December 18, 2025, and is solely responsible for the information contained therein.